Navigation Links
Array BioPharma Announces Exercise And Closing Of Underwriters' Over-Allotment Option
Date:12/5/2012

BOULDER, Colo., Dec. 5, 2012 /PRNewswire/ -- Array BioPharma Inc. (NasdaqGM: ARRY) announced today the sale of 2,700,000 shares of its common stock pursuant to the exercise of the over-allotment option granted to the underwriters in connection with Array's previously announced underwritten public offering of 18,000,000 shares of its common stock at a public offering price of $3.65 per share. The total net proceeds to Array, including from the exercise of the over-allotment option, were $70.9 million, after deducting underwriting discounts and estimated expenses. Jefferies & Company, Inc. and J.P. Morgan Securities LLC acted as joint book-running managers for the offering, with Piper Jaffray & Co., Stifel Nicolaus Weisel and William Blair acting as co-managers.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO )

The shares were sold pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC"). This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. 

A final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's web site at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained from either: Jefferies & Company, Inc., Equity Syndicate Prospectus Department, at 520 Madison Avenue, New York, New York, 10022, or by calling (877) 547-6340, or by emailing Prospectus_Department@Jefferies.com; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling (866) 803-9204.

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small‑molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly‑owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. 

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements concerning the expected use of proceeds of the offering and other statements that are other than statements of historical facts. These statements involve significant risks and uncertainties. Because these statements reflect our current expectations concerning future events, our actual events could differ materially from those anticipated in these forward-looking statements as a result of many factors. Additional information concerning factors that may cause actual events to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of Array's most recent Annual Report on Form 10-K, in our other periodic reports and filings with the Securities and Exchange Commission and in the prospectus supplement related to the offering. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Array on the date hereof, and we undertake no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

CONTACT:

Tricia Haugeto


(303) 386-1193


thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. John A. Orwin Joins Array BioPharma Board Of Directors
2. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
3. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
4. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
5. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
6. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
7. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
8. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
9. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
10. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
11. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... Massachusetts (PRWEB) , ... May 17, 2017 , ... ... company specializing in medical device compliance and commercialization, has just released version 9.0 ... of work into this latest version of Cockpit,” says David Cronin, CEO of ...
(Date:5/18/2017)... ... May 17, 2017 , ... G-CON Manufacturing, Inc., the ... Officer, Maik Jornitz, was recognized as a Top 10 Industry Influencer on The ... “involved in bettering the pharma industry and bringing life-changing medicines to market” across ...
(Date:5/16/2017)... ... May 16, 2017 , ... Genedata, a leading provider ... User Group Meetings, which will be held in Boston, Cambridge/UK, Shanghai, and ... in screening data analysis and learn about the latest advances in screening technologies ...
(Date:5/16/2017)... ... May 16, 2017 , ... Cynvenio Biosystems, Inc. ... ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 ... to quickly and accurately identify tumor-related genetic mutations that can be treated with ...
Breaking Biology Technology:
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/20/2017)... Germany , March 20, 2017 At this ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG ... is this year,s CeBIT partner country. At the largest German ... biometrics in use: fingerprint, face and iris recognition as well as DERMALOG´s ... ...
Breaking Biology News(10 mins):